bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD Disclosure

bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Regulation FD Disclosure
Item 7.01

Story continues below

Regulation FD Disclosure.

On June 15, 2018, bluebird bio, Inc. (“bluebird”) will conduct an investor webcast summarizing clinical data from the Northstar (HGB-204), Northstar-2 (HGB-207) and HGB-206 clinical studies of its LentiGlobin product candidate being presented at the 23rd Congress of the European Hematology Association in Stockholm, Sweden.A copy of the presentation is furnished to this report as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

On June 15, 2018, bluebird issued two press releases announcing updated clinical data being presented at the 23rd Congress of the European Hematology Association in Stockholm, Sweden from the Northstar (HGB-204) and Northstar-2 (HGB-207) clinical studies of its LentiGlobin product candidate in patients with transfusion-dependent β-thalassemia, and the HGB-206 clinical study of its LentiGlobin product candidate in patients with severe sickle cell disease.

The full text of bluebird’s press releases regarding the announcements are filed as Exhibits 99.2 and 99.3 to this Current Report on Form 8-K and are incorporated herein by reference.

Item 7.01

Financial Statements and Exhibits.

(d) Exhibits


bluebird bio, Inc. Exhibit
EX-99.1 2 blue-ex991_26.htm EX-99.1 PRESENTATION blue-ex991_26.pptx.htm EHA Analyst & Investor Webcast June 15,…
To view the full exhibit click here

About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

An ad to help with our costs